NRXP Logo

NRx Pharmaceuticals, Inc. (NRXP) 

NASDAQ
Market Cap
$15.3M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
634 of 775
Rank in Industry
345 of 433

Largest Insider Buys in Sector

NRXP Stock Price History Chart

NRXP Stock Performance

About NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and …

Insider Activity of NRx Pharmaceuticals, Inc.

Over the last 12 months, insiders at NRx Pharmaceuticals, Inc. have bought $0 and sold $0 worth of NRx Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at NRx Pharmaceuticals, Inc. have bought $409,877 and sold $686,775 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 70,000 shares for transaction amount of $20,125 was made by Hurvitz Chaim (director) on 2023‑08‑30.

List of Insider Buy and Sell Transactions, NRx Pharmaceuticals, Inc.

2023-08-30Purchasedirector
70,000
0.0777%
$0.29$20,125+4.57%
2023-08-30Purchasedirector
35,000
0.0432%
$0.32$11,197+4.57%
2023-08-23PurchaseChief Scientist
100,000
0.135%
$0.33$33,000+16.90%
2023-08-22PurchaseChief Scientist
200,000
0.2614%
$0.32$64,400+9.93%
2022-12-16PurchaseCHIEF EXECUTIVE OFFICER
50,000
0.0773%
$1.17$58,500-55.52%
2022-12-16PurchaseCHIEF FINANCIAL OFFICER
30,000
0.0436%
$1.10$33,000-55.52%
2022-12-07Saledirector
400,000
0.4224%
$1.00$400,000-63.19%
2022-11-30Saledirector
8,441
0.0134%
$1.50$12,700-60.42%
2022-11-29Saledirector
13,730
0.0228%
$1.50$20,651-58.70%
2022-11-28Purchasedirector
6,750
0.0102%
$1.25$8,413-54.32%
2022-11-25PurchaseCHIEF FINANCIAL OFFICER
16,337
0.0241%
$1.11$18,215-49.65%
2022-11-18Purchasedirector
40,408
0.0593%
$1.10$44,449-47.89%
2022-11-17Saledirector
33,018
0.0433%
$1.05$34,745-51.07%
2022-11-17Purchasedirector
171,780
0.2312%
$1.08$185,522-51.07%
2022-11-16Saledirector
133,719
0.1975%
$1.02$136,393-42.86%
2022-11-16Purchasedirector
287,812
0.4126%
$0.99$284,934-42.86%
2022-11-11Saledirector
49,200
0.0753%
$1.01$49,510-38.75%
2022-07-29Sale
784,063
1.5019%
$1.01$791,433-6.94%
2022-06-03Sale
115,657
0.1594%
$0.67$76,947+0.54%
2022-06-01PurchaseChief Scientist
100,000
0.1543%
$0.58$58,000+29.02%

Insider Historical Profitability

<0.0001%
Hurvitz Chaimdirector
570000
4.713%
$1.2740<0.0001%
Javitt Jonathan CChief Scientist
446332
3.6905%
$1.2731+29.02%
ACKERMAN RICHARDPresident and CEO
225000
1.8604%
$1.2711
Gorovitz Aarondirector
105000
0.8682%
$1.2710
Willard Stephen HCHIEF EXECUTIVE OFFICER
50000
0.4134%
$1.2710<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$679.56M13.461.44M-0.35%-$2.42M0.01
AdvisorShares$290.12M5.75614,793-4.33%-$13.14M20.87
Geode Capital Management$198.24M3.93419,954+1.95%+$3.79M0.02
BlackRock$137.19M2.72290,7140%+$0<0.01
Renaissance Technologies$89,000.001.76188,780-5.84%-$5,515.94<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.